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Antigen-induced arthritis in rats is associated
with increased growth-associated protein 43–
positive intraepidermal nerve fibres remote
from the joint
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Abstract
Introduction: Pain in arthritis may be experienced in regions outside the affected joint, and hyperalgesia may even
be widespread. The spread of pain is usually attributed to mechanisms in the central nervous system. We investigated
whether rats with antigen-induced arthritis (AIA) exhibit peripheral changes in skin innervation remote from the
inflamed joint.
Methods: After immunization, unilateral AIA in the knee joint was induced in rats. Intraepidermal nerve fibre density
was determined by immunohistochemical staining for protein gene product 9.5 (PGP 9.5) and for nerve fibres
expressing calcitonin gene–related peptide (CGRP), substance P (SP), transient receptor potential vanilloid 1
(TRPV1; the heat and capsaicin receptor), β-tubulin, and growth-associated protein 43 (GAP-43; a marker of
regenerating nerve fibres) in paw pad skin and back skin. Cluster of differentiation 11b (CD11b)-positive
macrophages and CD3-positive T cells were quantified in skin, and macrophages were quantified in the lumbar
dorsal root ganglia. In addition, pain-related behaviour was assessed.
Results: Intraepidermal nerve fibre density (PGP 9.5) and the numbers of fibres expressing CGRP, SP, TRPV1, or β-tubulin
did not show a significant change in the acute (3 days) or chronic phase (21 days) of AIA compared with control rats
that were only immunized. However, paw skin and back skin revealed a significantly higher number of nerve
fibres expressing GAP-43 at both the acute and chronic stages of AIA. The skin of arthritic rats in these regions
did not contain a greater density of CD11b and CD3 immune cells than the skin of control rats. Enhanced expression
of GAP-43 in nerve fibres of the skin was not related to hyperalgesia in the joint, but it accompanied persistent
secondary cutaneous hyperalgesia in the skin remote from the inflamed joint.
Conclusions: Although the innervation of the skin remote from the joint did not show significant abnormalities
of the other nerve fibre markers, the rapid and persistent increase of GAP-43 expression is conspicuous. The data
suggest that immune-mediated arthritis is associated with changes in skin innervation remote from the inflamed
joint, although the skin is not inflamed, which may contribute to symptoms in nonarticular tissue remote from
the affected joint.
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Introduction
Chronic joint diseases such as rheumatoid arthritis and
osteoarthritis are usually associated with chronic pain in
the affected joints. Careful clinical examination has shown,
however, that pain is often not restricted to the affected
joints. Patients with localized osteoarthritis and rheuma-
toid arthritis often exhibit allodynia (a reduction of pain
thresholds in the innocuous intensity range) and hyper-
algesia (increased pain perception on noxious stimulation)
in the entire limb [1, 2]. These phenomena are reproduced
in experimental arthritis models such as antigen-induced
arthritis (AIA) [3, 4]. Research in humans and experimental
models suggests that the spread of pain is due to neuronal
mechanisms in the central nociceptive system, such as the
sensitization of spinal cord neurons with expansion of
receptive fields (central sensitization) [5, 6], sensitization of
cortical pain–processing areas [7], reduced activity of
endogenous inhibitory systems descending from the
brainstem, and others [8, 9]. Such changes may initially be
induced by enhanced nociceptive inputs from sensitized
peripheral nociceptors [10, 11].
However, pain states are not entirely characterized by
augmented functional activity in the peripheral and central
nociceptive systems. An intriguing finding is the change of
the innervation density of diseased joints. Inflamed synovial
tissue derived from experimental arthritis and from patients
with rheumatoid arthritis showed a significant reduction of
nerve fibre density. Some authors reported a reduction of
peptidergic sensory afferents [12–16], whereas others
described mainly a reduction of sympathetic nerve fibres
[17]. A recent study reported a significant reduction of
nerve fibres in the synovium of patients with osteoarthritis
[18], but areas of sprouting of nerve fibres were also
reported in affected joints [19].
Changes of innervation density are likely to be caused
by local factors in the joint. However, to our knowledge,
whether changes of the innervation density in joint dis-
eases are restricted to the affected joint, or whether such
changes also occur remote to the afflicted joint, has
never been systematically tested. We therefore addressed
this question in the present study using the AIA model
in the rat, an animal model of monoarticular inflamma-
tion usually induced in the knee joint, which reproduces
major aspects of clinical rheumatoid arthritis. Rats with
AIA show a highly reproducible pathology with well-
defined acute and chronic states. Pronounced inflamma-
tion of the affected knee joint with local swelling and
hypersensitivity, as well as hyperalgesia in areas remote
from the inflammatory process (e.g., the noninflamed
contralateral knee and the paws), have been described
[3, 20]. Specifically, we asked whether the density of
intraepidermal nerve fibres (IENFs) is altered in the
paws and the back skin (regions far from the knee joint).
To investigate this question, we performed staining for
protein gene product 9.5 (PGP 9.5), a structural nerve
marker. We also quantified the IENFs expressing the
neuropeptides calcitonin gene–related peptide (CGRP)
and substance P (SP), both peptides are released from
nerve fibres and contribute to neurogenic inflammation;
the ion channel transient receptor potential vanilloid 1
(TRPV1), the heat and capsaicin receptor [21]; and the
cytoskeletal protein β-tubulin. Furthermore, we studied
growth-associated protein 43 (GAP-43), which is associ-
ated with nerve regeneration [22]. In order to identify in-
flammatory changes in the skin, we labelled skin sections
for cluster of differentiation 11b (CD11b) (macrophages)
and CD3 (T cells). We found that the paw pad skin and
the back skin of rats with AIA showed stable numbers of
PGP 9.5–positive IENFs and that the number of CGRP-
positive, SP-positive, TRPV1-positive, and β-tubulin–
positive IENFs in the paw pad skin also stayed stable, all
in the absence of inflammatory signs. Interestingly, how-
ever, the AIA rats exhibited significantly enhanced num-
bers of GAP-43–positive IENFs in both the acute and
chronic stages of AIA.
Methods
Animals
The study on AIA was performed on 25 female Lewis
rats (age 6–8 weeks initially, 160–190 g; Charles River
Laboratories, Sulzfeld, Germany). All experiments were
carried out in accordance with the European Communities
Council Directive (86/609/EEC) for the care and use of
laboratory animals and were approved by the Thuringian
State Office of Food Safety and Consumer Protection,
Department of Consumer Protection, Veterinary, Pharma-
ceuticals (registration number 02-013/08).
Antigen-induced arthritis
Arthritis was induced as previously described [3]. In brief,
with an interval of 7 days, rats (n = 25) were immunized
by two subcutaneous injections of 500 μg of methylated
bovine serum albumin (mBSA; Sigma, Deisenhofen,
Germany) prepared in saline, emulsified with 500 μl of
complete Freund’s adjuvant (Sigma) supplemented with
2 mg/ml Mycobacterium tuberculosis strain H37Ra (Difco;
Becton Dickinson, Sparks, MD, USA). Fourteen days after
the second injection, monoarticular arthritis was induced
by a further injection of mBSA (500 μg in 50 μl of
saline) into the left knee joint cavity (n = 20). The five
immunized-only rats served as controls.
Either at 3 days (n = 10, acute AIA) or at 21 days (n = 10,
chronic AIA) after induction of AIA, the rats were anes-
thetized by intraperitoneal injection of sodium thiopentone
(120 mg/kg Trapanal; Byk Gulden, Konstanz, Germany)
and killed by transcardial perfusion with heparin-enriched,
phosphate-buffered saline (PBS) and 4 % phosphate-
buffered formalin.
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Assessment of swelling and pain-related behaviour
For the assessment of swelling of the knee joint, the
mediolateral diameter of each knee was measured with a
vernier calliper (Mitutoyo, Neuss, Germany) as described
previously [3]. The difference between the diameter of
the noninflamed and inflamed knees for each animal
and testing day indicates the relative swelling.
Using an incapacitance tester (Linton Instrumentation,
Norfolk, UK), weight-bearing of the inflamed hind limb
was assessed as a functional measure of pain-related
guarding behaviour. The animals were placed with their
hind paws on scales inside a plastic cage, and the weight
force on the two scales was measured three consecutive
times while the animals sat calmly in the cage after
acclimation. From these averaged values, the relative
resting weight (expressed as a percentage) of the inflamed
hind limb was evaluated [weight of inflamed hind limb ×
100 %/(weight of inflamed hind limb + weight of nonin-
flamed hind limb)], as described previously [23].
Primary hyperalgesia at the inflamed knee was assessed
with a dynamometer (Correx, Bern, Switzerland) [24]. At
the level of the joint space on the lateral side of the knee
joint, increasing pressure was applied with the dynamom-
eter until the animals attempted to escape or vocalized.
The applied weight force was read in grams. A cutoff value
was defined at 250 g to prevent tissue damage. Testing was
performed once for each animal on each testing day to
avoid nociceptive sensitization due to repeated testing.
As previously described [3, 4], secondary hyperalgesia at
the paw was evaluated by testing paw withdrawal thresh-
olds to mechanical stimulation using a dynamic plantar
aesthesiometer (Ugo Basile, Comerio, Italy). For this test,
the animal rested on a mesh floor and a blunt filament
touched the hind paw on the plantar surface with increas-
ing force until the animal withdrew its leg. The weight force
needed for this reaction was measured in grams. After ha-
bituation to the device (15 min), three measurements were
recorded and the mean was used as the mechanical hyper-
algesia threshold value. Animals were tested before induc-
tion of AIA (baseline) and on days 3 (acute AIA), 7, 14, and
21 (chronic AIA) after induction of AIA. All pain-related
tests were performed on ten acute AIA animals and ten
chronic AIA animals, except for the assessment for second-
ary hyperalgesia, which was performed on five animals per
group.
Tissue processing and immunostaining
After the animals were killed, hind paw pad skin (five
immunized controls, ten ipsilateral acute and chronic
AIA rats, and five contralateral acute and chronic AIA rats),
lumbar paraspinal back skin (five immunized controls and
ten contralateral acute and chronic AIA rats), and lumbar
dorsal root ganglia (DRGs) from spinal levels L1–L5 (ten
ipsilateral acute AIA, nine ipsilateral chronic AIA, five
contralateral acute AIA, and five contralateral chronic
AIA rats) were dissected separately. The specimens were
then processed and immunostained as described previously
[25]. Briefly, AIA tissues were immersed in Zamboni’s fixa-
tive (2 % wt/vol formalin, 0.1 M phosphate, 15 % vol/vol
saturated picric acid) for 1 h at room temperature and then
stored in PBS containing sucrose and sodium azide at 4 °C.
The optimally orientated specimens were embedded in op-
timal cutting temperature compound (Tissue-Tek OCT;
RA Lamb, Eastbourne, UK) and snap-frozen. Frozen
specimens were sectioned (30-μm and 15-μm thicknesses)
using a cryostat (Bright Instruments, Huntingdon, UK),
and sections were collected on precoated glass slides
(VWR International, Lutterworth, UK). Sections were
then air-dried, and endogenous peroxidase was blocked by
incubating the sections in industrial methylated spirits
containing 0.3 % vol/vol hydrogen peroxide for 30 min.
After rehydration to PBS, the sections were incubated
overnight at 4 °C with primary antibodies to the structural
nerve marker PGP 9.5 (1:40,000, 30-μm sections, paw pad
skin and back skin; UltraClone Ltd, Wellow, UK), the
cytoskeletal protein β-tubulin (1:2000, 30-μm sections,
paw pad skin only; R&D Systems, Minneapolis, MN,
USA), the neuropeptides CGRP (1:4000, 30-μm sections,
paw pad skin only; Chemicon International, Chandler’s
Ford, UK) and SP (1:2000, 30-μm sections, paw pad
skin only; Chemicon International), the ion channel
TRPV1 (1:200, 30-μm sections, paw pad skin only; Glax-
oSmithKline, Harlow, UK), and GAP-43 (1:2000, 30-µm
sections, paw pad skin: Dr. G.P. Wilkin, Imperial College
London, London, UK; 1:20,000, 30-μm sections, back skin:
Sigma-Aldrich, Gillingham, UK) [26]. Different primary
antibodies to GAP-43 were applied for the two types of
skin owing to the better quality of staining achieved with
the correspondent antibody, which could be explained by
structural differences in glabrous and hairy skin. Further-
more, primary antibodies to inflammatory cell markers
CD11b for macrophages (1:100, 15-μm sections, paw pad
skin only; AbD Serotec, Kidlington, UK), CD3 for T cells
(1:200, 15-μm sections, paw pad skin only; Abcam,
Cambridge, UK), and ED1 (CD68) for macrophages
(1:200, 15-μm sections, DRGs; AbD Serotec) were
used. Thicker (30-μm) sections were used to increase
the sensitivity for markers of nerves, particularly fine,
penetrating IENFs, whereas thinner (15-μm) sections
were optimal for cells detected with inflammatory cell
markers. Sites of primary antibody attachment were
revealed using a standard nickel-enhanced immunoperox-
idase method, providing a black immunopositive reaction
product [27]. The sections were counterstained for nuclei
with 0.1 % wt/vol aqueous neutral red and mounted in a
xylene-based mountant before analysis. Control experi-
ments were performed by omission of the primary
antibodies.
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Quantification of immunostaining
IENFs immunoreactive to PGP 9.5, CGRP, SP, β-tubulin,
and GAP-43 were counted in a blinded manner along
the length of the tissue section (approximately 3–8 mm)
according to the guidelines developed by the European
Federation of Neurological Societies (EFNS) [28]. Thus,
only nerve fibres visibly crossing the basement mem-
brane of the epidermis were counted. For assessment of
whether a fibre crossed the basement membrane, the
focus of the microscope was adjusted to follow the nerve
fibre’s course within the dermis and epidermis. Nerve fi-
bres that branched in the epidermis were counted as
one; nerves branching below or within the basement
membrane were counted as separate units. Nerve frag-
ments within the epidermis were not counted [28].
Three nonadjacent sections from each animal were ana-
lysed for PGP 9.5; a further three separate sections for
GAP-43 (for paw pad and back skin); and a single sec-
tion for CGRP, SP, and β-tubulin (for paw pad skin only).
The length of the epidermis was measured on images
captured using an Olympus DP70 camera mounted on
an Olympus BX50 microscope using Olympus analySIS
software (version 5.0 for Windows; Olympus, Hamburg,
Germany). The results are expressed as nerve fibres per
millimetre length of epidermis.
CD11b and CD3 immunoreactivity in the dermis and
ED1 immunoreactivity in the DRGs were quantified by
computerized image analysis. Images were captured
using an Olympus DP70 camera mounted on an Olympus
BX50 microscope and analysed using Olympus analySIS
software. After applying the colour separation for red to
blank out the counterstaining, positive immunostaining
was highlighted by setting the grey-level detection limit to
a fixed threshold, and the area of highlighted immunore-
activity obtained as a percentage of the field scanned. The
threshold was kept constant for all specimens analysed
that were immunostained with the same marker. For the
skin (one section per animal) and DRGs (three nonadjacent
sections per animal) five and three microscopic fields
(magnification × 40) were analysed, respectively, and
the mean values were used in statistical analysis.
Statistical analysis
Descriptive statistics were created and statistical tests were
performed using Prism version 5.03 for Windows software
(GraphPad Software, San Diego, CA, USA). Group differ-
ences for the immunostaining data were assessed using
the nonparametric Mann–Whitney U test (two-tailed).
Behavioural changes were examined with the Wilcoxon
matched-pairs signed-rank test (two-tailed) and intra- and
interobserver correlations as well as IENF correlations
with Spearman’s correlation coefficient. Significance was
assumed at p < 0.05.
Results
Knee swelling and pain-related behaviour
Injection of mBSA into the knee joints of immunized
rats caused unilateral arthritis. Swelling of the injected
knee was pronounced during the first 3 days and de-
creased nearly to the prearthritic baseline until day 21.
The difference in knee joint diameters was significantly
increased (p = 0.0059) for the acute AIA vs. baseline
values (Fig. 1a).
Animals with AIA showed asymmetric weight-bearing,
putting significantly more weight on the noninjected
joint in the acute state compared with baseline values
(p = 0.002). This pain-related guarding behaviour sub-
sided gradually by day 21 (chronic state) (Fig. 1b).
Rats withdrew their legs or vocalized when pressure
was applied onto the knee. The mechanical pain
thresholds on the knee were significantly decreased in
the acute state of AIA compared with baseline values
(p = 0.0058), demonstrating primary hyperalgesia at the
inflamed knee. By day 21, the mechanical thresholds had
increased again to values close to baseline (Fig. 1c).
Withdrawal thresholds for monofilament stimulation
of the hind paw pad in rats with AIA were lower than,
but not significantly different from, baseline values (acute
vs. baseline p = 0.0625, chronic vs. baseline p = 0.125, n = 5
for acute AIA and chronic AIA groups). This indicates a
trend towards secondary hyperalgesia remote from the
inflammation (Fig. 1d).
Intraepidermal nerve fibres in paw pad and back skin
In rat hind paw pads and back skin, intense PGP 9.5–
immunoreactive subepidermal nerve fibres of various cali-
bres were present along the length of the dermal–epidermal
junction. Many fine-calibre nerve fibres penetrated into the
epidermis (IENFs), some extending almost to the stratum
corneum (Fig. 2a–c, ipsilateral paw pad skin). In paw pad
skin, a similar pattern was seen for CGRP-immunoreactive
nerve fibres, but with clearly fewer fibres overall (Fig. 2d–f,
ipsilateral paw pad skin), as well as for SP-, TRPV1-, and
β-tubulin–positive fibres. These observations applied to all
samples from the three groups examined (immunized
controls, acute AIA, and chronic AIA), with no obvious
differences in numbers of nerve fibres between groups
for either marker.
Counts of IENFs per millimetre length of epidermis of
AIA rats remained at about the same level as in controls
in sections immunostained with antibodies to PGP 9.5,
CGRP (Fig. 3a and c, ipsilateral paw pad; Fig. 3b, contra-
lateral back skin), SP, TRPV1, and β-tubulin. The numbers
of IENFs that were positive for PGP 9.5 are represented in
Table 1, numbers of IENFs that were positive for CGRP,
SP, TRPV1, or β-tubulin are represented in Table 2.
Skin sections immunostained with the antibody to
GAP-43 also revealed intense staining of subepidermal
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nerve fibres. Control animals showed only few labelled
IENFs (Fig. 4a), but apparently more IENFs were found
in acute or chronic AIA rats (Fig. 4b and c, ipsilateral
paw pad skin). The same observations were made for
back skin sections.
Counts of GAP-43–immunoreactive IENFs were in-
creased significantly in paw pad skin from rats with
acute (p = 0.0127) and chronic (p = 0.0007) AIA as com-
pared with controls (Fig. 5a, ipsilateral). The same applied
for numbers of GAP-43–positive IENFs in the contralat-
eral back skin (acute AIA vs. controls p = 0.0080, chronic
AIA vs. controls p = 0.0193; Fig. 5c). These changes in
GAP-43 counts also occurred in the contralateral paw
(n = 5) with the increase of GAP-43 being significant in
acute AIA (p = 0.0159), but not in chronic AIA (p = 0.0952),
compared with controls (Fig. 5b). The numbers of IENFs
that were positive for GAP-43 are represented in Table 3.
The numbers of GAP-43–immunoreactive IENFs per milli-
metre paw pad skin and per millimetre back skin correlated
positively (R = 0.6023, p = 0.0014; Fig. 5d).
Intra- and interobserver agreements for the counts of
IENFs were highly significant, as verified by correlations
(intraobserver reliability for paw pad skin tested on two
counts each for ten randomly chosen slides: R = 0.9879,
p < 0.0001; interobserver reliability for paw pad skin
tested on one count by two observers for ten randomly
chosen slides: R = 0.8303, p = 0.0047).
Relationship between behavioural data and GAP-43–positive
IENFs
In further analyses, we asked whether the number of GAP-
43–positive IENFs is correlated to different parameters in
assessment of pain-related behaviour. Figure 6 shows plots
of different pain parameters and GAP-43–positive IENFs
in the skin of the left paw of individual animals in the acute
and chronic AIA groups. Because all the rats that were
tested for nociceptive behaviour before induction of AIA
were used for the induction of AIA (see Fig. 1), we used
another five immunized control rats to determine the
baseline of GAP-43–positive IENFs. These animals did not
undergo behavioural testing. For the display of these data
in Fig. 6, we therefore used the typical range of the values
of behavioural parameters before induction of AIA
(see Fig. 1). The baseline data of Fig. 1 correspond to
values of our previous studies [3, 4, 29] [i.e., the weight-
bearing is symmetric, the mechanical threshold at the non-
inflamed knee is slightly below 250 g (250 g is the cutoff
value, average of baseline values here 234.5 g ± 20.6 g), and
the mechanical threshold at the paw is around 30 g (average
here 27.9 g ± 7.6 g)].
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Fig. 1 Joint swelling and pain-related behaviour. a The ipsilateral knee joint showed pronounced swelling in the acute state of antigen-induced arthritis
(AIA) compared with baseline values obtained before induction of AIA. b Animals with acute AIA bore significantly less weight on the inflamed hind limb
compared with baseline values. c Withdrawal thresholds for mechanical stimulation of the knee joint were significantly decreased in the
acute state of AIA. d Withdrawal thresholds for monofilament stimulation of the paw pad decreased in animals with AIA, but the values
did not reach statistical significance. Baseline values for acute and chronic AIA were pooled for the graphs, as there were no significant
differences between the values in these two groups. **p < 0.01
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At the acute stage of AIA, in which the values of the
pain parameters indicated pronounced hyperalgesia, the
values of GAP-43–positive IENFs were scattered, ex-
tending from the normal range to distinct increases
(Fig. 6a – c). However, at the chronic stage of AIA, the
animals showed a strong reversal of weight-bearing and
primary hyperalgesia, but all rats exhibited an increase
of GAP-43–positive IENFs (Fig. 6a and b). Secondary
hyperalgesia at the ipsilateral paw remained visible
(Fig. 6c). These data suggest that the change of GAP-43
expression is a dynamic process starting at the acute
stage of AIA. However, they do not indicate a simple,
straight association between GAP-43 expression and
pain.
Inflammatory cell markers in paw pad skin and DRGs
Throughout the dermis of the ipsilateral rat paw
pad CD11b-immunoreactive (macrophages) and CD3-
immunoreactive (T cells) cells appeared to be of similar
density within the three groups examined (Fig. 7a and b).
This was confirmed by image analysis of CD11b and CD3
staining, which did not reveal any significant differences
(Fig. 7c and d). This indicates that there was no inflamma-
tory process in the paw pad remote from the inflamed
knee joint.
ED1-immunoreactive cells (macrophages) were detected
around sensory neuronal perikarya of lumbar DRGs (Fig. 8a
– c). They appeared to be more numerous in acute AIA
rats than in control and chronic AIA animals in both ipsi-
Fig. 2 Intraepidermal nerve fibres (IENFs) in ipsilateral rat paw pad skin. Nerve fibres immunopositive for protein gene product 9.5 (PGP 9.5) (a–c)
and calcitonin gene–related peptide (CGRP) (d–f) in controls (a, d), acute AIA (b, e), and chronic AIA rats (c, f). Turquoise arrowheads indicate fine-calibre
intraepidermal nerve fibres that were counted according to the European Federation of Neurological Societies' counting rules, thus visibly
crossing the basement membrane between epidermis and dermis. For evaluation of IENF density, the focus of the microscope was adjusted while we
analysed the individual sections. Therefore, not all IENFs that are marked by turquoise arrowheads can be followed all the way through the epidermis in
the images. Thicker fibres along the dermal–epidermal junction are subepidermal nerve fibres. Numbers of IENFs that reacted with antibodies against
PGP 9.5 and CGRP did not change in animals with AIA compared with immunized-only controls. Original magnification × 40
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and contralateral DRGs. Image analysis of ED1 immuno-
staining showed a highly significant increase (p = 0.0007) in
acute AIA animals compared with controls on the ip-
silateral side (Fig. 8d) and on the contralateral side
(p = 0.0079).
Relationship between ED1 immunoreactivity in lumbar DRGs
and GAP-43-positive IENFs as well as ED1 and behavioural
data
We next examined potential correlations between ED1
in the lumbar DRGs and GAP-43–positive IENFs in the
paw pad and between ED1 and pain-related behaviour.
Figure 9a demonstrates the increased ED1 immunoreac-
tivity and therewith invasion of macrophages into the
lumbar DRGs in the acute phase of AIA and its decline
back to the level of control values in the chronic phase.
Numbers of GAP-43–positive IENFs started to increase in
the acute stage of AIA and were strongly elevated in the
chronic stage. The plot in Fig. 9 clearly depicts a lack of
strict correlation between macrophages in the DRGs and
the density of GAP-43–positive IENFs at this time point.
However, the invasion of macrophages into the DRGs
for acute and chronic AIA rats was correlated with
weight-bearing (R = −0.7930, p < 0.0001) (Fig. 9b) and
with primary hyperalgesia of the knee (R = −0.7116,
p = 0.0006) (Fig. 9c). Control values were not in-
cluded in this analysis, as control animals did not undergo
behavioural testing, as mentioned above (see Fig. 6).
Nevertheless, the averaged baseline values of acute and
chronic AIA animals before induction of AIA that were
used for the plot to depict the potential position of control
values seemed to lie within the area that would be expected
for overall correlation. In contrast, ED1 in DRGs and sec-
ondary hyperalgesia in the paw were not strictly correlated,
as the decrease of the pain threshold persisted and did not
fully reverse in the chronic phase of AIA (Fig. 9d). This un-
derlines the existence of different mechanisms for the de-
velopment of primary hyperalgesia in the inflamed region
and secondary hyperalgesia remote from the affected joint.
Discussion
In the present study, we investigated whether localized
arthritis in the knee joint causes neuronal changes in the
skin remote from the joint. Neither overall IENF density
nor the numbers of fibres expressing CGRP, SP, TRPV1,
or β-tubulin showed a significant change in the acute or
chronic phase of AIA compared with control rats. In
contrast, the paw and back skin revealed a significantly
higher number of nerve fibres expressing GAP-43 in
both the acute and chronic stages of AIA. Importantly,
the skin of arthritic rats in these regions did not contain
a higher density of CD11b and CD3 immune cells than
these regions in control rats. However, the lumbar DRGs











































Fig. 3 Measurement of intraepidermal nerve fibres (IENFs) in the paw pad and back skin. Numbers of IENFs per millimetre in control rats,
acute antigen-induced arthritis (AIA) rats, and chronic AIA rats, which are immunopositive for protein gene product 9.5 (PGP 9.5) (a, b) and cal-
citonin gene–related peptide (CGRP) (c) in the paw pad (a, c) and back skin (b). Counts of IENFs immunopositive to PGP 9.5 and CGRP did not
show significant changes
Table 1 Numbers of protein-gene product 9.5 (PGP 9.5)–
positive intraepidermal nerve fibres (IENFs)
Controls Acute AIA Chronic AIA Average SD
Ipsilateral paw
pad skin
26.42 ± 3.75 25.51 ± 6.71 25.60 ± 6.02 5.27
Back skin 9.14 ± 2.87 10.39 ± 2.57 11.89 ± 3.20 2.86
Numbers of IENFs per mm epidermis that were positive for PGP 9.5 in the left
(ipsilateral) paw pad skin and in the lumbar paraspinal back skin are presented
as mean ± standard deviation. The average SD is the average standard
deviation between counts of the three evaluated sections per animal. There
were no significant changes in counts of IENFs for stainings with PGP 9.5
Table 2 Numbers of intraepidermal nerve fibres in paw pad
skin for other nerve fibre markers
Controls Acute AIA Chronic AIA
CGRP 10.57 ± 2.13 12.21 ± 2.12 11.50 ± 1.88
SP 5.38 ± 1.05 4.87 ± 2.17 5.27 ± 1.30
TRPV1 7.17 ± 2.44 6.92 ± 5.41 6.46 ± 4.65
β-tubulin 26.63 ± 7.69 23.58 ± 6.54 22.34 ± 3.89
Numbers of IENFs per mm length of epidermis that were positive for
calcitonin gene-related peptide (CGRP), substance P (SP), transient receptor
potential vanilloid 1 (TRPV1), and β-tubulin in left (ipsilateral) paw pad skin are
presented as mean ± standard deviation. There were no significant changes in
counts of IENFs for these nerve fibre markers
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Fig. 4 (See legend on next page.)
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of both the inflamed and noninflamed sides did exhibit a
pronounced invasion of macrophages in the acute stage
of inflammation.
GAP-43 has received considerable interest in basic as
well as clinical neuroscience research because significant
changes of GAP-43–positive nerve fibres were identified
in human disease states. A reduction of IENF density is
considered a hallmark of classical small-fibre peripheral
neuropathy. In patients with neuropathy in the course of
type 2 diabetes, IENF density was significantly lower
than in controls [30, 31], corresponding to early dysfunc-
tion of sensory small-diameter nerve fibres and to deple-
tion of SP and nerve growth factor (NGF) in the skin
[32]. The IENF density was also reduced in patients with
fibromyalgia concomitant with signs of impaired small-
fibre function [33]. Interestingly, changes of IENF density
are often associated with alterations of GAP-43. Thus, the
reduction of IENF density in both type 2 diabetes [30] and
fibromyalgia [33] is accompanied by a reduction of GAP-43.
GAP-43–immunoreactive IENFs were also decreased in
highly inflamed psoriasis skin areas [34], whereas a signifi-
cant increase of GAP-43–positive IENFs was shown in
human allergic contact dermatitis in eczematous skin
compared with control skin [35, 36]. Thus, alterations in the
expression of GAP-43 are found in different disease condi-
tions, inviting discussion of the role of GAP-43.
GAP-43 is a membrane protein associated with axonal
development, axonal regeneration, remodelling, and
neuronal plasticity [22, 37]. It is highly expressed in the
central nervous system (CNS) during development,
(See figure on previous page.)
Fig. 4 Intraepidermal nerve fibres (IENFs) in ipsilateral rat paw pad skin. Nerve fibres immunopositive for growth-associated protein 43 (GAP-43) in
control rats (a), acute antigen-induced arthritis (AIA) rats (b), and chronic AIA rats (c). Turquoise arrowheads indicate fine-calibre IENFs that were counted
according to the European Federation of Neurological Societies' counting rules, thus visibly crossing the basement membrane between epidermis and
dermis. For evaluation of IENF density, the focus of the microscope was adjusted while we analysed the individual sections. Therefore, not all IENFs that
are marked by turquoise arrowheads can be followed all the way through the epidermis in the images. Thicker fibres along the dermal–epidermal junction
are subepidermal nerve fibres. Numbers of IENFs that reacted with antibodies against GAP-43 increased significantly after induction of AIA.
Original magnification × 40
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Fig. 5 Growth-associated protein 43 (GAP-43)–positive intraepidermal nerve fibres (IENFs) in paw and back skin and their correlation. Numbers of
IENFs per millimetre epidermis immunopositive for GAP-43 in control rats, acute antigen-induced arthritis (AIA) rats, and chronic AIA rats (a–c).
Numbers of IENFs marked by antibodies against GAP-43 increased significantly in the left paw pad skin (ipsilateral) and in lumbar back skin from
paraspinal right (contralateral) in the acute and chronic state of AIA, compared with immunized-only controls (a, c). GAP-43–positive IENFs were
significantly increased in the right paw pad skin (contralateral) in the acute state of AIA but not in the chronic state (b). Numbers of IENFs positive
for GAP-43 per millimetre of left paw pad skin correlated to those of lumbar back skin (d). R = 0.6023, p = 0.0014; *p < 0.05, **p < 0.01, ***p < 0.001
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assisting neuronal path finding and branching until ma-
ture synapses are formed. In some CNS regions, GAP-43
is expressed throughout adulthood, and it is thought to
be involved in processes such as memory formation [38].
GAP-43 immunoreactivity was also found in a subset of
PGP 9.5–immunoreactive sensory and autonomic fibres
in the dermis and epidermis and around sweat glands,
hair follicles, and blood vessels [22, 39]. GAP-43 is con-
sistently expressed in these nerve fibres [22], suggesting
that a proportion of these peripheral nerve fibres are in
a state of restructuring. GAP-43 is upregulated after
nerve injury, which is followed by regrowth of the injured
nerve, and the upregulation is thought to be triggered by
the interruption of the retrograde axonal transport [40, 41].
GAP-43 is critically involved in nerve regrowth because
depletion of GAP-43 in neuronal growth cones leads to de-
ficient spreading and branching of nerve fibres [42],
whereas overexpression of GAP-43 induces spontaneous
nerve sprouting and a highly potentiated sprouting re-
sponse with branching after nerve lesions in transgenic
mice [43].
Whether alterations of GAP-43 are per se (and causally)
associated with sensory changes such as pain or sensory
abnormalities is currently unknown. In clinical studies, re-
searchers often use changes in the expression of GAP-43
as an indicator of neuronal changes, mostly as an indica-
tor of regeneration or regenerative potential. However,
researchers in most studies have not reported whether pa-
tients had symptoms such as pain or sensory abnormal-
ities. Interestingly, investigators in one study reported that
patients with diabetic neuropathy and pain had higher
GAP-43/PGP 9.5 ratios than patients with diabetic neur-
opathy without pain [44]. However, firm conclusions on
the role of GAP-43 in sensory function are premature.
The present data show some aspects related to this
problem. First, in the present experiments, the density of
GAP-43–positive IENFs per se did not correlate to
hyperalgesia, because at day 3 of AIA the numbers of
GAP-43–positive IENFs were scattered from the normal
range to enhanced levels but the drop of pain thresholds
was pronounced in all animals. Furthermore, at day 21,
weight-bearing and primary hyperalgesia at the knee
were clearly reversed; yet, all rats exhibited an increase
of GAP-43–positive IENFs in the ipsilateral paw at this
time point. This suggests that the reversal from a signifi-
cant pain state in the deep tissue may be associated with
Table 3 Numbers of growth-associated protein 43 (GAP-43)–positive intraepidermal nerve fibres (IENFs)
Controls Acute AIA Chronic AIA Average SD
Ipsilateral paw pad skin 9.16 ± 1.47 14.65 ± 5.36 19.48 ± 3.73 5.14
Significance of the group difference against the control group: p = 0.0127 p = 0.0007
Contralateral paw pad skin 9.16 ± 1.47 14.34 ± 3.39 12.95 ± 3.89 4.13
Significance of the group difference against the control group: p = 0.0159 p = 0.0952
Back skin 6.17 ± 1.62 9.54 ± 2.37 10.10 ± 2.31 2.68
Significance of the group difference against the control group: p = 0.0080 p = 0.0193
Numbers of IENFs per millimetre epidermis that were positive for GAP-43 in the left (ipsilateral) and right (contralateral) paw pad skin and in the lumbar
paraspinal back skin are presented as mean ± standard deviation. The average SD is the average standard deviation between counts of the three evaluated
sections per animal. Significances of the group differences were assessed using the nonparametric Mann Whitney test
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Fig. 6 Plots for growth-associated protein 43 (GAP-43)–positive intraepidermal nerve fibres (IENFs) in paw skin and behavioural data of antigen-induced
arthritis (AIA) rats. a Relationship between the relative weight-bearing on the inflamed hind limb and IENFs marked by antibodies against GAP-43 in the
ipsilateral paw pad skin. Relative weight-bearing for control animals was defined as 50 %, with equal weight on both legs. Control values are parenthesized.
b Plot of the mechanical threshold at the inflamed knee and GAP-43–positive IENFs in the ipsilateral paw pad skin. Control values in parentheses were set
at 234.5 g, which was the average baseline value for animals before induction of AIA (standard deviation was ±20.6 g). c Relationship between
the mechanical threshold of the ipsilateral paw pad and GAP-43–positive IENFs in the ipsilateral paw pad skin. Control values in parentheses
were determined as the mean of baseline values from acute and chronic AIA animals before induction of AIA (27.9 g ± 7.6 g)
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an increase of GAP-43–positive IENFs (at least in some
areas) (see Fig. 5). However, Fig. 1d shows a persistent
reduction of the mechanical withdrawal thresholds upon
von Frey hair stimulation at the ipsilateral paw, indicat-
ing persistence of secondary (cutaneous) hyperalgesia.
Although this reduction was not statistically significant
in the present study, we found a statistically significant
persistent thermal hyperalgesia at the ipsilateral paw at
day 21 in previous studies [4, 29]. We did not test for
thermal hyperalgesia in the present study (to avoid any
damage to the skin), and therefore we have no informa-



































Fig. 7 Inflammatory cell markers in ipsilateral rat paw pads. Cells in the dermis and image analysis (% area) of cluster of differentiation 11b (CD11b)
immunoreactivity (a, c; macrophages) and CD3 immunoreactivity (b, d; T cells) in control and antigen-induced arthritis (AIA) rats. Arrows mark typical
CD11b-positive (a) and CD3-positive (b) cells. There was no significant change of inflammatory cells in paw pad skin of AIA rats compared with controls.






















Fig. 8 Macrophages in ipsilateral rat lumbar dorsal root ganglia (DRGs). Anti-CD68 antibody (ED1) immunoreactivity in control rats (a), acute
antigen-induced arthritis (AIA) rats (b), and chronic AIA rats (c) and image analysis (% area) of ED1 immunoreactivity (d). There were significantly more
macrophages in the DRGs of animals with acute AIA compared with controls. Arrows mark typical ED1-positive cells. *Satellite cells, n = neurons.
Original magnification × 40. ***p < 0.001
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and GAP-43 expression. However, in the AIA model,
thermal hyperalgesia at the paw develops quickly in paral-
lel to mechanical hyperalgesia [3, 4, 29], and thus neither
mechanical nor thermal hyperalgesia per se seems to be
strictly correlated with changes of GAP-43 expression.
It is important to note that the behavioural changes in
experimental arthritis models correspond to observa-
tions in humans. Rats with unilateral arthritis in the
knee joint also exhibit local mechanical hyperalgesia at
the contralateral healthy knee joint, and they show
enhanced sensitivity to mechanical and thermal stimuli
at the hind paws [3, 4]. Widespread pain was also noted
in bilateral experimental arthritis [45, 46]. Correspond-
ingly, widespread pain was documented in patients with
arthritis [1, 2]. Moreover, changes in skin sensation or
cutaneous nociceptor function in arthritis were also re-
ported in humans. Capsaicin-induced cutaneous vasodila-
tion (flare) and hyperalgesia were increased in patients
with rheumatoid arthritis and fibromyalgia [47–50], sug-
gesting neuronal changes in areas of secondary hyperalge-
sia. The studies in patients match observations in animal
experiments, which showed changes of nociceptive thresh-
olds in areas remote from the inflamed joint. Such
phenomena are usually explained by central mechanisms,
but the present study indicates that peripheral changes
should also be considered.
Whether humans with rheumatoid arthritis show en-
hanced GAP-43 expression has not been explored, to our
knowledge. However, patients with rheumatoid arthritis
do not have significantly altered IENF densities compared
with healthy subjects [51]. This data is concordant with
our findings in AIA rats, where IENF densities determined
with primary antibodies against PGP 9.5 did not change
either. Interestingly, patients with systemic lupus erythe-
matosus and primary Sjögren syndrome presented with
significantly decreased IENF densities compared with con-
trol subjects [51].
Although the sensory consequences of altered GAP-43
expression are unclear, the consensus based on many
studies is that neuropathy or local inflammatory changes
may be associated with changes in GAP-43 expression
and that an upregulation of GAP-43 indicates a regener-
ation of nerve fibres, whereas a reduction of GAP-43 is
associated with a loss of regenerating nerve fibres. The
novel finding of the present study is that the GAP-43
expression in nerve fibres was increased in skin remote
A B
C D
Fig. 9 Anti-CD68 antibody (ED1) immunoreactivity in lumbar dorsal root ganglia (DRGs) and its correlations with growth-associated protein 43
(GAP-43)–positive intraepidermal nerve fibres (IENFs) and behavioural data. Plot of the time course of GAP-43–positive IENFs in the left paw pad
skin and ED1 immunoreactivity (macrophage invasion) in the lumbar DRGs (a). Correlation between ED1-immunoreactive cells in the DRGs and
weight-bearing. Relative weight bearing for control animals was defined as 50 %, with equal weight on both legs. Control values are parenthe-
sized (b). Correlation between ED1-immunoreactive cells in the DRGs and primary hyperalgesia. Control values in parentheses were set at 234.5 g,
which was the average baseline value from animals before induction of AIA (SD was ±20.6 g) (c). Relationship of ED1 immunoreactivity and sec-
ondary hyperalgesia in the paw. Control values in parentheses were determined as the mean of baseline values from acute and chronic AIA ani-
mals before induction of AIA (27.9 g ± 7.6 g) (d)
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from an inflamed joint. The present findings are the first,
to our knowledge, to indicate that IENFs remote from the
joint show changes in arthritis.
The question regarding mechanisms which might be
involved in the upregulation of GAP-43 in nerve fibres fol-
lowing arthritis in the skin remote from the joint is intri-
guing. Our data indicate that this process started within the
first 3 days of AIA and persisted in some skin regions up to
21 days. In the AIA model, lumbar DRG neurons do not
express activating transcription factor 3, a marker for neur-
onal damage, at the acute or chronic stage [20]. Thus, there
is no evidence for a neuropathic process. CD11b- and
CD3-immunoreactive cells in the ipsilateral rat paw were
found at a similar density in the dermis of control rats, rats
with acute AIA, and rats with chronic AIA. Thus, we did
not obtain any evidence for an inflammatory process in the
paw pad remote from the inflamed knee joint. Preliminary
data do not indicate that the upregulation of GAP-43 is
correlated to NGF in the paw (unpublished data from E
Jochmann, MK Boettger, P Anand, HG Schaible, 2015).
In the present study, we observed, as in two previous
studies, a bilateral invasion of macrophages into the
lumbar DRGs of both the inflamed and noninflamed
sides [20, 52]. This invasion was seen mainly at the acute
stage of AIA [20]. Careful examination of the invading
macrophages showed that they resembled the tumour
necrosis factor–activated type of macrophage, a subtype
of M1 macrophages. These macrophages do not express
inducible nitric oxide synthase and do not destroy neurons,
but they do release mediators such as interleukin (IL)-6
and are able to stimulate DRG neurons [52]. An important
aspect is that these macrophages seem to be distributed
throughout the DRGs [20, 52]. Thus, they may influence
the cell bodies of DRG neurons supplying different target
tissues in the leg. This observation supports the conclusion
that localized arthritis may affect sensory neurons beyond
those supplying the inflamed joint. In fact, the upregulation
of some receptors, such as IL-1 receptor type I, during
AIA is observed in a large proportion of DRG neurons in
the lumbar DRGs [4].
Whether the invasion of macrophages into the DRGs
is linked to enhanced GAP-43 expression is unknown.
The data shown in Fig. 9 allow at least some speculation.
The invasion of macrophages was strongly correlated
with changes in weight-bearing and primary hyperalgesia
at the inflamed knee joint in rats with AIA. At day 21 of
AIA, primary hyperalgesia and asymmetric weight-bearing
were reversed and macrophage invasion disappeared.
However, secondary hyperalgesia persisted at this point
and GAP-43 expression was increased. It may be specu-
lated, therefore, that the invasion of macrophages into the
DRGs triggers changes in the neurons which lead to an
upregulation of GAP-43 and the persistence of secondary
hyperalgesia remote from the joint.
Conclusions
On the basis of the present study, we report the novel ob-
servation that changes of innervation in arthritis models
occur not only in the inflamed joint but also in healthy skin
remote from the joint. Because GAP-43 is thought to indi-
cate processes of structural neuronal plasticity, the present
findings suggest that arthritis is associated with neuronal
changes in skin innervation remote from the inflamed
joint. Although the precise role of enhanced GAP-43
expression in mechanisms of pain is not known, the data
show that localized immune-mediated arthritis may cause
more widespread neuronal alterations in the peripheral
nervous system. Such neuronal changes may contribute to
long-lasting secondary hyperalgesia in the skin remote
from the inflamed joint. Our findings should stimulate
research into the regulation and functional importance of
GAP-43 and regenerating nerve fibres in arthritis and
chronic, widespread pain.
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